The general meeting adopted the annual report 2024 consisting of the statutory financial statements and the consolidated financial statements of Implantica AG for the financial year 2024, acknowledging the reports of the auditors.

The general meeting resolved to carry forward the net loss for the financial year 2024 in accordance with the adopted balance sheet and to no payment of dividend.

The general meeting resolved to discharge the members of the board of directors, the executive management and the auditors from liability for their services in the financial year 2024.

The general meeting resolved to approve the total remuneration of the board of directors of TEUR 106 and of the executive management of TEUR 821 for the financial year 2024. The total remuneration includes fixed compensation, pension contributions and a long-term share-based incentive plan. Executive Management is made up of the Chief Executive Officer, Chief Financial Officer, Chief Strategy Officer and Chief Corporate Affairs Officer.

The general meeting resolved to re-elect Liselott Kilaas, Johan Bojs, Tomas Puusepp and Stephan Siegenthaler as board members for a term of office until completion of the next AGM of shareholders. Liselott Kilaas was also re-elected as chairman and Johan Bojs was re-elected as vice-chairman of the board of directors until the end of the next annual general meeting.

The general meeting resolved to re-elect Johan Bojs as member and chairman and to elect Tomas Puusepp as member of the nomination and remuneration committee until completion of the next AGM.

The general meeting resolved to re-elect Philipp Wanger, Attorney-at-law, Neugasse 17, 9490 Vaduz, Liechtenstein as independent proxy until the next general meeting of shareholders.

The general meeting resolved to re-elect KPMG (Liechtenstein) AG, Aulestrasse 2, 9490 Vaduz, Liechtenstein as auditor for the financial year 2025.

The general meeting resolved to amend Article 4a para. 1 of the Articles of Association to authorize the Board of Directors to, with or without deviation from the shareholders' preferential rights, resolve on new share issues.

The general meeting resolved to amend Article 4 para. 5 of the Articles of Association to authorize the board of directors to, with or without deviation from the shareholders' preferential rights, resolve on new share issues for the exercise of contingent capital comprising conversion rights or options in relation with convertible debt instruments.

The minutes of the annual general meeting with information regarding each resolution proposal adopted at the general meeting will be available at www.implantica.com.

For further information, please contact:
Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on May 15, 2025 at 20:20 CET.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.